Qiyu Biotech
Qiyu Biotech is an innovative macromolecular drug developer
About Qiyu Biotech
Qiyu Biotechnology (Shanghai) Co., Ltd., which also operates under the name QureBio, is a clinical-stage biopharmaceutical company established in July 2017. The firm was founded by Xiangdong Qu, a scientist with approximately two decades of experience in new drug research and development at prominent U.S. companies, including Amgen, Eli Lilly, and Cell Therapeutics Inc. This background in international pharmaceutical R&D provides the foundation for the company's strategic direction. The core team is composed of scientists with deep expertise in antibody engineering and manufacturing processes.
The company's primary business is the research and development of innovative macromolecular drugs to address unmet clinical needs in refractory cancers, autoimmune diseases, inflammatory disorders, and metabolic diseases. Its operational model is centered on leveraging a proprietary suite of technology platforms to create a pipeline of therapeutic candidates. These platforms include systems for hybridoma antibody humanization, phage display, single-domain antibodies, and antibody engineering, such as its I2T platform for bispecific and multispecific antibodies. Qiyu Biotech's revenue generation model involves advancing its internally developed assets through clinical trials and forming strategic partnerships with other pharmaceutical firms for co-development and commercialization. The company has established collaborations with entities like BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific.
Qiyu Biotech's therapeutic pipeline features several key drug candidates. Its lead product, Q-1802, is a bispecific antibody targeting both Claudin18.2 and PD-L1 for the treatment of solid tumors like gastric cancer. This candidate has received Investigational New Drug (IND) clearance from both U.S. and Chinese regulatory agencies and is advancing through clinical trials. Another significant asset, Q-1801, is a dual-target antibody for SIRPα and PD-L1, which also has clinical trial approvals in the U.S. and China. The company has successfully raised significant capital through multiple funding rounds, including a Series C1 financing of nearly CNY 100 million in June 2025, to advance its clinical programs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Huangpu, China
- Open positions
- None listed
- Dealroom signal
- 16.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jun 2025 | $14M | $138M | Efung Capital | ↗ |
| SERIES B✓Equity / VC | Dec 2021 | $28M | $110M | Shanghai Pudong Science and Technology Investment · Yuanhe Puhua · Bank of Communications · Tianfu Sanjiang Capital | ↗ |
Growth signals
Latest recorded traffic for Qiyu Biotech is 650 monthly website visits, down 14.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qiyu Biotech in the Huangpu ecosystem
The Qiyu Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Shanghai Pudong Science and Technology Investment- YPYuanhe Puhua
- BCBank of Communications
- TCTianfu Sanjiang Capital
- LCLongmen Capital
- GUGuoshun
- LHLihe Hongxin
Series B and later1 investor entered at this stage
- ECEfung Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qiyu Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qiyu Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









